Markets

AstraZeneca To Present 100+ Cancer Research Abstracts, Including Five Phase III Trials, At ESMO 2026

Oct 19, 2026 · 07:10 AM ET· updated 1h ago

CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patientsSAFFRON results will highlight clinical benefit of adding

Why It Matters

AstraZeneca is showing a lot of cancer research at a big medical conference. Watch to see if their new medicines work as hoped and help patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

AZN164.27

-1.14 (-0.69%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.